| dc.contributor | 科管智財所 | |
| dc.creator (作者) | 陳秉訓 | |
| dc.creator (作者) | Chen, Ping-Hsun | |
| dc.date (日期) | 2020-02 | |
| dc.date.accessioned | 21-Jan-2021 09:37:59 (UTC+8) | - |
| dc.date.available | 21-Jan-2021 09:37:59 (UTC+8) | - |
| dc.date.issued (上傳時間) | 21-Jan-2021 09:37:59 (UTC+8) | - |
| dc.identifier.uri (URI) | http://nccur.lib.nccu.edu.tw/handle/140.119/133643 | - |
| dc.description.abstract (摘要) | This article explores Shire Development, LLC v. Watson Pharmaceuticals, Inc., 848 F.3d 981 (Fed. Cir. 2017) and illustrates some implications for designing around a MMX-based tablet drug, Lialda. The MMX technology is known for its lipophilic matrix and hydrophilic matrix in a tablet, while the former matrix is dispersed within the latter one. In Shire Development, LLC, the disputed claim recited a Markush limitation for the hydrophilic matrix and excludes unlisted materials from the hydrophilic matrix. On the other hand, the accused generic drug included magnesium stearate, a lipophilic material, in its hydrophilic matrix and, therefore, did not infringe the disputed patent. The case opens a door for generic drug companies to design around the patented MMX technology underlying Lialda. | |
| dc.format.extent | 201396 bytes | - |
| dc.format.mimetype | application/pdf | - |
| dc.relation (關聯) | Biotechnology Law Report, Vol.39, No.1, pp.25-32 | |
| dc.title (題名) | A Design-Around Solution for a MMX-Based Tablet Drug Comprising Mesalazine—A Lesson from Shire Development, LLC v. Watson Pharmaceuticals, Inc. | |
| dc.type (資料類型) | article | |
| dc.identifier.doi (DOI) | 10.1089/blr.2019.29155.pc | |
| dc.doi.uri (DOI) | https://doi.org/10.1089/blr.2019.29155.pc | |
